Lucid Diagnostics Inc. (LUCD) Stock Analysis & Investment Frameworks
Lucid Diagnostics Inc. (LUCD) stock analysis on Invetso. Review Lucid Diagnostics Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Lucid Diagnostics Inc. Company Overview
- Exchange: NASDAQ Global Market
- Sector: Healthcare
- Industry: Medical - Devices
- Country: US
Lucid Diagnostics Inc. Key Financial Metrics
- Market Cap: $74.49M
- Revenue: $4.71M
- ROE: -404.34%
- ROIC: -141.44%
- Dividend Yield: N/A
About Lucid Diagnostics Inc.
Lucid Diagnostics Inc. is a commercial-stage medical technology firm focused on diagnostic solutions. The company's primary objective is to serve patients afflicted with gastroesophageal reflux disease (GERD), commonly referred to as chronic heartburn or acid reflux, especially those at increased risk of developing precancerous esophageal conditions or the particularly aggressive esophageal adenocarcinoma. Their key product offerings include EsoGuard, an internally developed esophageal DNA test, and EsoCheck, a specialized device designed for collecting esophageal cells. Formed in 2018, Lucid Diagnostics Inc. has its headquarters in New York, New York, and operates as a subsidiary of PAVmed Inc.
Lucid Diagnostics Inc. Investment Frameworks
Invetso analyzes Lucid Diagnostics Inc. (LUCD) across the following frameworks:
- Lucid Diagnostics Inc. 10Y Growth Potential
- Lucid Diagnostics Inc. Scenario Analysis
- Lucid Diagnostics Inc. Risks & Opportunities
- Lucid Diagnostics Inc. Economic Moat
- Lucid Diagnostics Inc. Business Model
- Lucid Diagnostics Inc. Management
- Lucid Diagnostics Inc. SWOT Analysis
- Lucid Diagnostics Inc. Porter's 5 Forces
- Lucid Diagnostics Inc. PESTLE Analysis
- Lucid Diagnostics Inc. ESG Analysis